What is Alumis?
Headquartered in South San Francisco, Alumis is a precision medicine company dedicated to the development and commercialization of novel therapies for immune-mediated diseases. The company's core asset, ESK-001, represents a sophisticated allosteric tyrosine kinase 2 (TYK2) inhibitor designed to treat conditions such as plaque psoriasis and systemic lupus erythematosus. Furthermore, the company is expanding its reach into neuroinflammatory and neurodegenerative disorders with its CNS-penetrant candidate, A-005. By focusing on high-unmet-need indications, Alumis has positioned itself as a key player in the next generation of targeted biopharmaceutical innovation.
How much funding has Alumis raised?
Alumis has raised a total of $509M across 2 funding rounds:
Series C
$259M
Stock Offering
$250M
Series C (2024): $259M with participation from venBio Partners, Samsara BioCapital, and Foresite Capital
Stock Issuance/Offering (2024): $250M, investors not publicly disclosed
Key Investors in Alumis
venBio Partners
A life sciences investment firm that partners with industry leaders to develop innovative medicines, focusing on novel therapeutics for unmet medical needs.
Samsara BioCapital
An investment firm focused on creating transformative therapeutics by partnering with scientists and drug developers to support the next generation of breakthroughs.
Foresite Capital
A multi-stage investment firm that utilizes a data science-driven approach to transform healthcare by funding companies at the intersection of biology and technology.
What's next for Alumis?
With the recent influx of capital, Alumis is well-positioned to accelerate its clinical trial programs and scale its operational infrastructure. The strategic focus will likely remain on the successful execution of late-stage clinical studies for its lead TYK2 inhibitors, while simultaneously exploring potential partnerships to broaden the commercial reach of its pipeline. As the company matures, the emphasis will shift toward data readout milestones and potential regulatory filings, ensuring that its innovative therapeutic modalities reach patients suffering from chronic autoimmune and neurological conditions. The firm's ability to attract top-tier life sciences investors suggests a strong outlook for its long-term commercial viability and scientific impact.
See full Alumis company page
